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ABSTRACT 
About 50% of people living with the HIV infection in Italy are co-infected with HCV. In this group of patients, the pri-
mary cause of mortality is liver disease, which accounts for up to 14% of deaths. HIV/HCV co-infection also exposes 
patients to a higher risk of progression to AIDS, a faster evolution towards cirrhosis, more frequent drug toxicity, and 
lower tolerance for antiretroviral therapy. Moreover, HCV infection can play a part in increasing immune system de-
pression; neurological, cognitive and renal damage; and bone fragility. Hence an optimal antiretroviral regimen needs to 
be chosen for co-administration with anti-HCV therapy and timed appropriately to improve the prognosis of co-infected 
HIV/HCV patients. Unfortunately, however, data on the safety and efficacy of antiretroviral drugs in these patients is 
scarce, as are studies of pharmacokinetics in patients with advanced liver impairment. Furthermore, restoring adequate 
immune constitution seems not to slow the progression of liver disease, and the metabolic and hepatic toxicity of some 
antiretroviral drugs can even contribute to inflammatory and fibrogenic processes. It is therefore essential that HIV/ 
HCV co-infected patients receive only medications capable of ensuring the best immune recovery but possessing the 
lowest potential to trigger immune reconstitution syndrome or hepatic and metabolic damage. 
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1. Consensus Development 
The consensus meeting, held under the auspices of the 
Italian Society for Infectious and Tropical Diseases (So- 
cietà Italiana di Malattie Infettive e Tropicali—SIMIT) 
and the Italian Society for Sexually Transmitted Diseases 
(Società Italiana di Malattie Sessualmente Trasmessibili— 
SIMAST), and the patronage of the Italian Infectious 
Disease and Public Health Foundation (Fondazione di 
Malattie Infettive e Salute Internazionale—MISI) was 
funded by an unrestricted grant from ViiV Health Care, 
Italy. 
The first draft of “Antiretroviral Therapy in HIV/HCV 
Co-infection, Italian Consensus Workshop” was written 
by Dr. Paola Nasta, Dr. Anna Maria Cattelan, Dr. Ivana 
Maida and Dr Francesca Gatti with the help of Erika 
Chiari. The draft was reviewed by Prof. Raffaele Bruno 
(IRCCS San Matteo Hospital, University of Pavia, Divi- 
sion of Infectious and Tropical Diseases, Pavia, Italy), 
Prof. Roberto Cauda (Catholic University of the Sacred  
Heart, Institute of Clinical Infectious Diseases, Rome, 
Italy), Dr. Simona Di Gianbenedetto (Catholic University 
of the Sacred Heart, Institute of Clinical Infectious Dis- 
eases, Rome, Italy), Prof. Giovanbattista Gaeta (Depart- 
ment of Clinical and Experimental Medicine and Surgery 
“F. Magrassi-A. Lanzara”, Second University of Naples, 
Italy), Dr. Francesco Mazzotta (Santa Maria Annunziata 
Hospital, Infectious Diseases Department, Florence, Italy), 
Prof. Evangelista Sagnelli (Department of Public Medi- 
cine, Section of Infectious Diseases, Second University 
of Naples, Italy), Prof. Gloria Taliani (La Sapienza Uni- 
versity, Institute of Infectious and Tropical Diseases, 
Rome, Italy) and Dr. Carlo Torti (University of Brescia, 
Institute of Infectious and Tropical Diseases, Brescia, 
Italy), and revised accordingly by Prof. Giampiero Carosi 
and Prof. Massimo Puoti. 
The following doctors participated in the work group: 
Marino Bonasso, Vanni Borghi, Federica Borghi, Silvana 
Caprioglio, Erika Chiari, Anna Maria Degli Antoni,  
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Palma Delle Foglie, Eugenia Di Meco, Gian Piero 
D’Offizi, Concetta Donato, Francesco Esperti, Roberto 
Gulminetti, Giancarlo Iaiani, Nicoletta Ladisa, Davide 
Motta, Myrvete Muca Perja, Giorgio Perboni, Emanuele 
Pontali, Vincenzo Portelli, Alessandro Ruggeri, Vincenzo 
Sangiovanni, Paolo Scerbo, Vincenzo Selva, Filomena 
Simeone, Hajrijie Skiti and Gabriella Verucchi.  
2. Introduction 
Human Immunodeficiency Virus (HIV) and Hepatitis C 
Virus (HCV) share common transmission pathways, al- 
though HCV is more efficiently transmitted through 
blood than the sexual route. It is unsurprising therefore 
that roughly half of the Italian population of HIV patients 
also test positive for HCV. In fact, HCV is the most 
prevalent cause of liver disease in co-infected Persons 
Living with HIV (PLWHIV), which is in turn the most 
common cause of non-AIDS-related mortality in these 
patients, accounting for up to 14% of deaths worldwide. 
In addition, HCV co-infection worsens immune depres- 
sion and contributes to neurological, cognitive and renal 
impairment, as well as bone fragility. It may also expose 
patients to a higher risk of progression to AIDS, to more 
frequent drug toxicity, and to decreased tolerance for 
antiretroviral therapy [1,2]. 
Nevertheless, combined antiretroviral therapy (cART) 
has been linked to a reduction in liver-related mortality in 
PLWHIV, acting via suppression of HIV replication and 
restoration of CD4 counts. That being said, data on the 
safety and efficacy of antiretroviral drugs in these sub- 
jects are still scarce, as are pharmacokinetic/pharmaco- 
dynamic studies in patients with advanced liver disease. 
It seems, however, that the timing of cART initiation and 
the choice of anti-HIV medications are critical for the 
prognosis of PLWHIV.   
Under the auspices of the Italian Society for Infectious 
and Tropical Diseases (Società Italiana di Malattie In- 
fettive e Tropicali—SIMIT), and Italian Society for Sexu- 
ally Transmitted Diseases (Società Italiana di Malattie 
Sessualmente Trasmissibil—SIMAST), a group of experts 
in the field of ART was invited to discuss the current 
risks and benefits of antiretroviral treatment in HIV/HCV 
co-infected patients, and to update the statements pub- 
lished following the first Italian Consensus Conference in 
2005.  
The experts prepared a draft of the consensus state- 
ments after a careful review of the current literature on 
three key issues of optimized antiretroviral treatment in 
HIV/HCV co-infected patients:  
1) Management of HIV/HCV in co-infected patients.  
2) Optimization of cART in HIV/HCV co-infected pa- 
tients who are not eligible for pegylated-interferon (PegIFN) 
and ribavirin (RBV) treatment, or those who are awaiting 
new anti-HCV treatment options. 
3) Optimization of cART in co-infected patients suita- 
ble for anti-HCV treatment with the current peg-IFN/ 
RBV regimen. 
Statements were graded for their strength and evidence 
based on the criteria adopted by the Infectious Diseases 
Society of America (IDSA) (Table 1), and scrutinized 
and discussed by a qualified group of Italian infectious 
disease specialists, hepatologists, and virologists, con- 
vened in Sirmione for a 2-day workshop. After a series of 
introductory lectures, the previously prepared statements 
were analysed and revised by the specialist physicians in 
work groups of 5 - 10. On the second day of the consen- 
sus meeting, the revised statements were presented in a 
plenary session by the leaders of each work group, and 
modified following a plenary discussion and vote using 
an electronic voting system. All participants expressed 
their agreement with each statement, ranking them on a 
scale of 1 (complete disagreement) to 9 (complete agree- 
ment). Statements were accepted only when all the 
agreement scores were between 7 and 9, otherwise they 
were reformulated and subjected to a new vote.  
2.1. Management of HIV/HCV in Co-Infected  
Patients  
Chronic hepatitis C is characterized by slow progression 
of fibrosis towards cirrhosis, triggered by liver inflam- 
mation; the evolution of cirrhosis towards decompensa- 
tion due to progressive portal hypertension and failure of 
liver function; and/or the onset of hepatocellular carci- 
noma (HCC). Hence, accurate staging of the liver disease, 
preventative measures, and early diagnosis of such com- 
placations are vital in HIV patients co-infected with 
HCV. 
2.1.1. Assessment of Liver Disease Stage 
Liver biopsy is still the gold standard for fibrosis staging, 
on condition that the liver fragment obtained is greater 
than 20 - 25 mm length and contains more than 10 portal 
tracts. However, biopsy is an invasive and expensive 
procedure that may on occasion be associated with se- 
vere complications, and is also prone to measurement 
error [3]. In contrast, non-invasive strategies have vari- 
ous advantages including lower cost and higher patient 
acceptability, making them easier to repeat after short 
intervals. Moreover, several studies have shown that 
non-invasive methods have similar prognostic accuracy 
 
Table 1. Levels of evidence and scoring of recommenda- 
tions.  




I-Properly randomized controlled trial
II- Other published studies 
III-Expert Opinion 
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in HCV/HIV co-infection and in patients with chronic 
hepatitis C alone. Biochemical parameters, namely the 
AST-to-platelet ratio index, FIB-4 score, FibroTest, Fi- 
broMeter, Hepascore and Zeng’s score, correctly stage 
fibrosis in the majority of patients and generally show 
high negative predictive values [4]. Likewise, liver stiff- 
ness measured by transient elastography (Fibroscan®) 
provides the same diagnostic accuracy in HIV/HCV co- 
infection and HCV mono-infection. In addition, liver 
stiffness seems to be a very useful prognostic marker for 
monitoring the progression of fibrosis over time, which is 
accelerated in co-infected HIV/HCV subjects [5]. 
Statement: although liver biopsy remains the gold 
standard for detecting fibrosis in HIV/HCV co-infected 
patients, non-invasive assays such as transient elastogra- 
phy and/or biochemical surrogate markers can be used in 
co-infected HIV/HCV patients, and are particularly use- 
ful for monitoring the progression of fibrosis over time 
(BII).  
The guidelines for treatment of complications in cir- 
rhosis patients in the general population can, for the mo- 
ment, be applied to cirrhotic PLWHIV. Although HCC is 
an increasing cause of death in these patients and data 
appears to show it progresses more rapidly in PLWHIV, 
this finding is controversial, and there is not yet enough 
data available to support different screening and man- 
agement procedures for HCC in PLWHIV [6,7]. 
Statement: early detection and management of compli- 
cations due to portal hypertension and ESLD in co-in- 
fected HCV/HIV patients is vital and should follow the 
same guidelines as for HCV mono-infected patients. Ul- 
trasound examination at 6-month intervals is the main- 
stay for hepatocellular carcinoma surveillance (AI). 
2.1.2. End Stage Liver Disease and Liver  
Transplantation  
It has been demonstrated that permanent discontinuation 
of cART in compensated cirrhotic patients has a signifi- 
cant link with liver decompensation and shorter survival 
times. Moreover, increased survival after the first episode 
of decompensation has been demonstrated in patients 
taking cART with respect to those discontinuing antiret- 
roviral treatments [8-10]. However, it has not been dem- 
onstrated that antiretroviral therapy is able to modify the 
risk of HCC in patients with HCV-related cirrhosis [11]. 
Statement: highly active antiretrovirals should be 
maintained in cirrhotic co-infected HCV/HIV patients to 
avoid accelerated progression to ESLD, particularly 
when decompensation occurs, to reduce the incidence of 
liver-related mortality (AII). 
Liver transplantation is currently a treatment option for 
HIV patients with ESLD or HCC, and in many countries, 
including Italy, HIV-infected patients have been given 
access to the national transplant programme since 2002, 
subject to the strict inclusion and exclusion criteria. 
However, in HCV/HIV co-infection, transplant outcomes 
are worse than those reported for HIV-negative patients, 
mainly due to more severe recurrence of HCV. In fact, 
recent studies have shown that survival after transplant 
may be up to 40% worse in co-infected HIV/HCV pa- 
tients than in patients with HCV infection alone. Never- 
theless, survival at 5 years post-transplant seems to be 
around 50% in HCV-infected PLWHIV with [12-20]. 
CD4 < 200, high MELD score at transplant, advanced 
donor age, HCV genotype-1 infection, and double liver- 
kidney transplantation have all been described as predic- 
tors of poor prognosis. 
Statement: co-infected HIV/HCV patients with ESLD 
or HCC should be periodically assessed for their eligibil- 
ity for liver transplantation (B III). Orthotopic liver 
transplant can be offered to selected HIV/HCV co-in- 
fected patients if they meet the eligibility criteria estab- 
lished by national transplant programmes. (B II).  
After transplant, the management of immunosuppres- 
sive therapy may be particularly troublesome in HIV- 
infected patients due to its interaction with antiretroviral 
drugs. Such drug—drug interactions require frequent 
drug dosage adjustments and monitoring (over- or under- 
dosing may increase the risk of drug-induced toxicity, 
transplant rejection and/or HIV viral rebound) [21]. 
Statement: to improve the outcome in co-infected 
HIV-HCV patients undergoing orthotopic liver transplan- 
tation (OLT), both pre transplant and post-transplant 
cART should be managed by a multidisciplinary team 
involving pharmacologists and infectious disease spe- 
cialists with expertise in OLT in HIV-infected patients 
(AII).  
2.2. Optimized cART in Co-Infected HIV/HCV  
Patients Not Eligible for PegIFN/RBV  
Treatment, or in Those Awaiting New  
Anti-HCV Treatment Options 
Antiretroviral therapy has the well-known advantage of 
slowing down hepatic disease progression. However, 
liver disease progression can be accelerated by drug- 
induced liver injury (DILI), which is more common in 
HCV co-infected PLWHIV. Acute and subacute DILI 
can be related to immune restoration, and chronic DILI 
can arise due to cART-induced hepatotoxicity and meta- 
bolic changes. DILI has been reported to occur in 15% - 
20% of HIV/HCV co-infected individuals. When cART 
was first introduced, these patients had an up to eight- 
fold risk of severe hepatic damage after starting cART 
with respect to patients with HIV alone. Interestingly, a 
higher risk of hepatotoxicity has been reported in patients 
carrying genotype 3 HCV with respect to the other geno- 
types [22,23].  
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2.2.1. DILI during Immune Reconstitution  
Inflammatory Syndrome (IRIS) 
An increase in anti-HCV specific immune response after 
cART initiation may lead to higher levels of transami- 
nase following a sudden increase in CD4+ T-cell count 
from a low baseline value [24-27]. DILI during IRIS is 
more frequent in advanced naïve patients who started 
cART with drugs able to dramatically decrease the HIV 
viral load. 
Statement: to reduce the risk of IRIS, cART should be 
started earlier in co-infected HCV/HIV persons (AIII). If 
patients have a high risk of developing DILI due to IRIS 
(CD4+ T-cell count level < 200 cell/mm3, moderate- 
severe liver disease and/or HCV genotype 3), they should 
be closely monitored, especially when fast-acting viral 
suppressors are prescribed (BIII). 
2.2.2. DILI Due to Direct Hepatotoxicty  
First and foremost, it is important to note that this type of 
toxicity differs from immune allergic reactions involving 
the liver, which are not related to HCV status. Indeed, 
NRTI hepatotoxicityis linked to depletion in mitochon- 
drial DNA, mainly caused by the thymidine analogue 
reverse-transcriptase inhibitors (NRTI) [28,29]. Being 
less toxic to the mitochondria, abacavir, tenofovir, lami- 
vudine and emtricitabine are safer options in chronic 
liver disease [30]. NNRTIs also present a high risk of 
DILI. Extensive data are recorded for efavirenz and 
nevirapine, [31] and the latter seems to cause a higher 
risk of DILI than the former [31,32], in particular when 
given once daily [33]. However, direct NNRTI-related 
DILI usually occurs beyond the third month of treatment, 
and an increased cumulative incidence has been reported 
for nevirapine [32]. It is thought that etravirine and ril- 
pivirine may grant better liver safety as compared to the 
older drugs of the same class, but little data is available 
at the present time [33].  
Tipranavir and higher doses of ritonavir have been as-
sociated with an increased incidence of DILI [34,35], but 
to date, hepatic safety of darunavir in HIV/HCV co-in- 
fected patients has not been extensively investigated. 
Nevertheless, a study conducted on HIV-infected patients, 
with or without HCV co-infection, enrolled in the Italian 
darunavir EAP showed a moderate increase in transami- 
nases in co-infected subjects, whether cirrhosis was pre- 
sent or not. However, it is not clear whether or not this 
increase was linked to the presence of the 200 mg ri- 
tonavir boosting [36]. It is known, however, that the 
pharmacokinetics of darunavir/ritonavir 600 mg/100 mg 
twice daily are not affected by mild (Child–Pugh classi- 
fication 1) or moderate (Child-Pugh classification 2) he-
patic impairment [37,38]. Furthermore, unboosted ata- 
zanavir 400 mg QD and fosamprenavir 1400 mg QD, 
boosted or unboosted by ritonavir, are commonly used 
with satisfying results in co-infected HIV/HCV subjects 
when TDM is available [39,40]. Moreover, registrative 
trials have demonstrated that raltegravir may produce an 
increase in AST/ALT of 3 - 4 degrees, but this occurred 
in no more than 2% - 3% of the treated population. Data 
on co-infected populations are still scarce, although a 
study conducted on 135 subjects treated with integrase 
inhibitor, 45 of whom were co-infected by HCV, showed 
that the risk of a 1 - 2 degree increase in transaminases 
was higher in co-infected (39.5%) vs. mono-infected 
HIV patients (9.1%). This was especially true when cho- 
lesterol was ≥200 mg/dl and raltegravir was co-adminis- 
tered with a protease inhibitor. In subjects with advanced 
hepatic disease, the AST/ALT increase was not signify- 
cantly higher [41,42]. 
Although hepatic toxicity events have been reported 
for some CCR5 inhibitors, the MOTIVATE trial revealed 
the considerable hepatic safety of maraviroc—after 48 
weeks the AST/ALT rate increase to 3 - 4 degree was 
0.6% - 3.7% [43,44]. Studies to evaluate the anti-in- 
flammatory and anti-fibrogenic effect of CCR5 inhibition 
with maraviroc are ongoing [45]. 
Statement: didanosine and stavudine should be 
avoided in co-infected HCV/HIV patients due to a risk of 
lactic acidosis (AII). NNRTI prescription should be indi- 
vidualized, and discouraged in those with grade 3 - 4 
transaminase elevation at baseline (BII). In general, 
nevirapine prescription should be discouraged in naïve 
patients (BIII), and is contraindicated at CD4 cell counts 
> 400 in males and >250/ml in females. Limited data ap- 
pear to indicate etravirine and rilpivirine for co-infected 
HIV/HCV patients (C I). PIs should be boosted with 100 
mg/day of ritonavir (but no more than 200 mg/day) 
(AI-II), although unboosted PIs are a reasonable means 
of optimizing cART in co-infected HIV/HCV patients. 
(AII) TDM, when available, should be used to monitor 
the correct dosage of NNRTIs and boosted or unboosted 
PIs. (AII) Raltegravir and maraviroc should be con- 
sidered as safe options for co-infected HIV/HCV patients 
with mild to moderate hepatic disease (AII). 
2.2.3. DILI Due to Metabolic Toxicity  
Changes in glucose and lipid metabolism contribute to 
the progression of hepatic fibrosis in patients with chro- 
nic hepatitis C through liver steatosis. This has also been 
reported in as much as 61% of HIV/HCV patients, in 
whom it is associated with a higher degree of liver fibro- 
sis [46]. Steatosis pathogenesis is multifactorial in these 
patients, but the metabolic effects of some antiretroviral 
drugs may contribute to liver steatosis and NASH, as 
both cause and effect of insulin resistance and increase in 
leptin plasma levels [47]. Indeed, long-term exposure to 
NRTIs and especially to “d-Drugs” is associated with 
insulin resistance, diabetes and increased serum lactates 
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[48]. Early-generation protease inhibitors also induced 
insulin resistance, as well as increasing triglycerides, total 
cholesterol, leptin and peptide C, while reducing HDL 
cholesterol and adiponectin [47]. Even though studies on 
the effect of many antiretrovirals in current use on liver 
steatosis are lacking, lipodystrophy and a high HOMA 
score have both displayed a significant link with ad- 
vanced liver fibrosis [49]. Raltegravir showed a neutral 
metabolic effect in clinical studies [50]. 
Statement: mitochondrial toxicity and insulin resis- 
tance appear to play a key role in cART-related liver 
steatosis, NASH, and consequently liver fibrosis pro- 
gression. Highly mitochondria-toxic antiretroviral drugs 
(AZT, DDI, D4T) should therefore be avoided (AII). 
Drugs with major effects on glucose metabolism also 
need to be used with caution (BII).  
2.2.4. cART in Co-Infected HIV/HCV Patients with  
Co-Morbidities  
A meta-analysis of 24 observational retrospective studies 
and several clinical trials found that HIV/HCV co-infec- 
tion is associated with increased risk of kidney disease, 
including proteinuria and renal failure [51]. The largest 
study of biopsy-proven renal disease has found that 
HIV/HCV-associated nephropathies reduced survival as 
compared to HCV mono-infection [52]. Furthermore, the 
10-year incidence of bone fractures was 3.6-fold higher 
in HCV co-infected patients, probably because patients 
with chronic liver disease have decreased BMD [53]. 
It has also been demonstrated that co-infected HIV/ 
HCV patients more frequently suffer from neurologic 
disturbances than mono-infected HIV patients [54] and 
also have higher rates of global cognitive impairment, 
especially in learning and memory [55]. Sensory neu- 
ropathy is a common complication of HIV infection, may 
be worsened by cART-related toxicity, and is associated 
with HCV infection, raising concerns about possible 
synergistic effects of these viruses on the peripheral 
nervous system [56].  
Statement: the renal function, bone metabolism, car- 
diovascular system and central and peripheral nervous 
systems of co-infected HIV/HCV patients may be af- 
fected by extra-hepatic manifestations of HCV. There- 
fore, in addition to appropriate screening and close fol- 
low-up of co-morbidities, the following recommenda- 
tions apply: 
1) An early switch to drugs with lower renal and bone 
toxicity when signs of impaired renal function and/or 
bone metabolism are detected (A-BI). 
2) In co-infected HIV/HCV persons with cardiovascu- 
lar risk, no different cART options are recommended 
with respect to mono-infected HIV patients (AIII). 
3) Patients with minor neurocognitive impairment 
(HAND) on efavirenz should receive close individual- 
ized follow-up (BIII). 
2.2.5. cART in Patients with ESLD 
Patients with ESLD need to be treated by a multidisci- 
plinary team (AIII). Antiretroviral treatment interruptions 
are an additional risk factor for accelerated cirrhosis pro- 
gression and liver-related mortality in HIV/HCV co- 
infection [57,58]. PLWHIV with concomitant ESLD in 
particular need continued effective antiretroviral therapy. 
However, this issue is complicated by the fact that some 
antiretroviral drugs require dosage adjustments to com-
pensate for reduced hepatic drug metabolism in ESLD 
[59]. 
Statement: co-infected HIV/HCV patients with ESLD 
should be maintained on cART (AII). No drugs are for- 
mally indicated in patients with a Child-Pugh score of 
C—limited data are available only for fosamprenavir 300 
BID plus ritonavir 100 mg/QD. TDM is highly recom- 
mended to optimize the dosage in patients with ESLD 
(AII). Off-label use and dosage of antiretroviral drugs 
should be considered only when supported by TDM. 
However, since TDM data are not validated in ESLD 
patients, any therapeutic decision should be based on 
immuno-virological and safety data (AII). 
2.3. Optimized c-ART in Co-Infected HIV/HCV  
Patients during Treatment with  
Peginterferon plus Ribavirin  
HCV- and HIV-infection highly influence each other’s 
progression. New data aimed at clarifying the patho- 
physiological mechanisms underlying this interaction 
strongly support the importance of early treatment of 
both infections [60-63]. 
2.3.1. HCV or HIV Therapy: What to Start First? 
Both Italian and European guidelines recommend that 
antiretroviral treatment should precede anti-HCV treat- 
ment in patients with a supposed rapid progression of 
HIV disease (HIV-RNA > 100,000 copies/mL or a CD4+ 
T-cells decay >100 cells/uL in the previous year) at any 
level of CD4 cell count, and in the case of CD4+ T-cell 
counts lower than 500 cells/uL because it may help attain 
a sustained virological response (SVR) [64,65]. Indeed, 
data from a large observational Italian study on treatment 
of HCV infection in HIV-infected patients seem to sup- 
port an earlier start of cART in co-infected subjects un- 
dergoing standard anti-HCV treatment (based on peg In- 
terferon and ribavirin), as suppression of HIV-RNA was 
significantly associated with “eradication” (SVR) of 
HCV infection [66].  
Statement: the eradication of HCV (sustained virologi- 
cal response-SVR) is of huge importance in co-infected 
HIV/HCV patients. Nevertheless, in subjects with de- 
tectable HIV-RNA and a stable CD4+ T-cell count, even 
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higher than 500/uL, the start of cART is recommended 
before commencing standard anti-HCV treatment. (BII) 
In co-infected HIV/HCV patients eligible for standard 
anti-HCV treatment with a CD4 + T-cell count between 
350 and 500/uL, cART should be commenced before anti- 
HCV treatment (BII). In patients not eligible for anti- 
HCV treatment, cART must be started immediately due 
to its protective effect on the progression of liver fibrosis 
(AII).   
A stable immune recovery is desirable before com- 
mencing anti-HCV treatment (AII). 
Co-infected HIV/HCV patients with undetectable 
HIV-RNA, CD4 + T-cell count < 200/uL and advanced 
liver disease should be treated with anti-HCV drugs, de- 
spite the lack of data in profoundly immunosuppressed 
patients (AII).  
2.3.2. The Influence of cART on the Outcome of  
Standard Anti-HCV Treatment  
The influence of cART on the outcome of standard anti- 
HCV treatment has not yet been fully clarified, and the 
data that is available comes mainly from retrospective 
analyses. Most of these studies suggest that cART has no 
impact on the achievement of SVR, with the exception of 
drugs that amplify the adverse effects of PegIFN/RBV 
(like zidovudine, stavudine or didanosine) [67,68]. Sev- 
eral studies have raised concerns about the potential 
negative interaction between abacavir and ribavirin, 
showing a significantly reduced rate of SVR in patients 
taking abacavir, mainly when ribavirin has to be admin- 
istered at reduced doses [69]. However, the postulated 
competition between abacavir and ribavirin for intracel- 
lular phosphorylation was not confirmed by an in vitro 
study [69]. Moreover, this impact of abacavir was not 
confirmed in other cohorts of co-infected HIV/HCV pa- 
tients treated with PegIFN and weight-based ribavirin 
[70].  
Some antiretroviral drugs induce insulin resistance, 
which has emerged as an important predictor of rapid 
virological response (RVR) and SVR in many studies, 
and this should be taken into account when selecting 
cART, even though to date there have been no trials to 
determine whether an insulin-resistance-guided shift of 
antiretroviral drugs may have a favourable effect on SVR 
[71,72].  
Finally, drug–drug interactions must be carefully con- 
sidered, especially in direct-acting antivirals (DAAs such 
as HCV-protease and polymerase inhibitors) [73-75]. To 
this end, several studies have described drug—drug in- 
teractions between boceprevir, telaprevir and antiretrovi- 
rals in normal subjects. The results of these studies are 
summarized in Table 2, which also reports which an- 
tiretrovirals can be given to candidates for treatment with 
boceprevir and telaprevir. That being said, pilot studies 
in which boceprevir was administered to patients taking 
anti-HIV protease inhibitors failed to confirm the poten- 
tial clinical significance of these interactions. No infor- 
mation is yet available regarding the new anti-HCV 
agents currently in phase II and III trials in HIV-infected 
patients, but drug—drug interactions between all classes 
of anti HCV DAA and antiretrovirals may be significant, 
with the possible exception of nucleosides/nucleotide 
polymerase inhibitors.   
Statement: in co-infected HIV/HCV candidates for 
both antiretroviral and anti-HCV treatment, it is ad- 
visable to start cART, or to modify it if required, at least 
4 - 8 weeks before starting anti-HCV therapy to take into 
account the potential interactions between antiretroviral 
drugs, PegIFN/RBV and the new DAAs. This will enable 
better management of any side effects caused by the 
cART regimen, giving the patient time to adapt (AIII). 
Statement: In HIV/HCV co-infected candidates for 
anti-HCV treatment, the cART regimen should have the 
following characteristics:   
 Efficacy: general principles for selecting cART in 
HIV-mono-infected subjects should be followed 
(AIII).  
 Pharmacodynamic interactions potentially causing an 
amplification of side effects of pegylated interferon 
and/or ribavirin need to be ruled out. 
 ddI ± d4T must be avoided because the combined use 
of these drugs with RBV increases the risk of mito- 
chondrial toxicity (pancreatitis, lactic acidosis) (AI). 
 AZT should be avoided due to an increased risk of 
myelotoxicity (anaemia, neutropenia) (BI). 
 EFV and boosted ATV may be used, but close moni- 
toring is advised as EFV may amplify the neuropsy- 
chiatric effects of pegylated interferon, while ATV, 
when given in combination with RBV, may increase 
levels of plasma bilirubin (CII). 
 Drugs with the lowest impact on insulin sensitivity 
should be chosen (BIII).  
 New ARV drugs with a low metabolic impact can be 
prescribed, but should currently be used with caution 
as so far there is no published clinical data concerning 
their use in anti HCV-treatment (clinical trials to 
study their use in this particular setting are recom- 
mended) (CIII). 
 In candidates for boceprevir and/or telaprevir, cART 
regimen should be switched to one without significant 
drug—drug interactions at least 4 - 8 weeks before 
starting anti-HCV therapy whenever possible (Table 
2). In patients whose cART regimen cannot be altered, 
three mutually exclusive scenarios should be con- 
sidered on an individual basis:  
Delay of anti-HCV therapy in patients with mild fibro- 
sis Cautious use of darunavir in telaprevir candidates and 
cautious use of atazanavir in boceprevir candidates, 
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Table 2. Summary of recommendations for antiretroviral drug administration in candidates for anti-HCV treatment. 
Antiretroviral 
drug class Drug 
Combination with
PegIFN + RBV
Combination with PegIFN + RBV 
+telaprevir 
Combination with PegIFN + 
RBV + BOC 
Zidovudine, Stavudine or Didanosine No additional toxicity 
Abacavir Consider alternative treatment for use with low ribavirin doses 
Lamivudine or Emtricitabine Can be used 
NRTI 
Tenofovir Can be used but eGFR should be monitored (increased exposure if not used with efavirenz)
Lopinavir + Ritonavir Can be used Not advised: significant DDI 
Darunavir + Ritonavir Can be used Not advised but could be considered in selected patients with no alternatives Not advised 
Atazanavir + Ritonavir Can be used Can be used 
Not advised but could be 
considered in selected patients 
with no alternatives 
Fosamprenavir + Ritonavir Can be used Not advised 
PI 
Tipranavir + Ritonavir Can be used Not advised due to potential interactions—no data on DDI 
Efavirenz Can be used Can be used with TPV 1125 t.i.d.  (consider additional costs) Not advised 
Nevirapine Can be used Not advised (potential interactions—data on DDI) 
Rilpivirine Can be used Can be used but QT interval  monitoring is advised Not advised (no data on DDI)
NNRTI 
Etravirine Can be used 
Raltegravir Can be used 
Others 
Maraviroc Can be used Not advised (no data on DDI) 
 
without other “allowed” anti-HIV treatment options. 
Withdrawal of cART for three months in candidates 
for telaprevir with CD4 > 500 and a CD4 nadir greater 
than 350. 
3. Conclusion 
While we await new anti-HCV drugs, which may consent 
interferon-free, all-oral, pangenotypic, and 100% effec- 
tive treatment of HCV, optimization of antiretroviral 
regimens may play a pivotal role in stabilizing and even 
improving the course of HCV co-infection in PLWHIV 
candidates for anti-HCV treatment and patients with ad- 
vanced liver disease. 
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